Prospects for using scleral cross-linking with riboflavin and ultraviolet A (UVA) in progressive myopia
Session Details
Session Title: Moderated Poster Session: News on Cornea
Venue: Poster Village: Pod 1
First Author: : E.Usubov RUSSIA
Co Author(s): : M. Bikbov V. Surkova M. Astrelin
Abstract Details
Purpose:
to assess the efficacy and safety of scleral cross-linking (SCL) with riboflavin/UVA in experiment.
Setting:
Ufa Eye Research Institute
Methods:
The influence of SCL on the biomechanical strength of the sclera was assessed on porcine cadaver eyes. Also the UVA absorption coefficients of intact and saturated with riboflavin scleral tissue were calculated. The effect of SCL on the structure and ultrastructure of the sclera was assessed using light and electron microscopy. Quantitative analysis of histological sections was carried out with the help of specialized software (the software for morphometric analysis 'VideoTesT Morphology', the software for the electronograms analysis 'iTEM'). The preservation of the eye structures after SCL was evaluated on rabbits in vivo with the help of light microscopy.
Results:
SCL led to an increase in biomechanical strength of the sclera. Scleral structure and ultrastructure were not disturbed. There were an increase in the density of collagen fibres by 8% and an increase in the diameter of collagen fibrils by 12%.
After SCL in rabbits in vivo there was a transient inflammatory reaction in the sclera. Inflammation gradually decreased and completely disappeared in a week after the procedure. There were no pathological changes in the retina, optic nerve and cornea.
The UVA absorption coefficient of the intact sclera was 4.91〖 mm〗^(-1), of the saturated sclera - 8.86 〖mm〗^(-1).
Conclusions:
SCL with riboflavin/UVA leads to an increase in the biomechanical strength of the sclera, an increase in the diameter of the collagen fibrils and the density of the scleral collagen fibres. At the same time, SCL is safe for eye structures of the laboratory animals if careful observance of procedure parameters is provided.
Financial Disclosure:
NONE
